vs
安捷伦科技（A）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Pediatrix Medical Group, Inc.的3.6倍（$1.8B vs $493.8M）。安捷伦科技净利率更高（17.0% vs 6.8%，领先10.1%）。安捷伦科技同比增速更快（7.0% vs -1.7%）。过去两年安捷伦科技的营收复合增速更高（6.9% vs -0.1%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
A vs MD — 直观对比
营收规模更大
A
是对方的3.6倍
$493.8M
营收增速更快
A
高出8.7%
-1.7%
净利率更高
A
高出10.1%
6.8%
两年增速更快
A
近两年复合增速
-0.1%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $493.8M |
| 净利润 | $305.0M | $33.7M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 9.9% |
| 净利率 | 17.0% | 6.8% |
| 营收同比 | 7.0% | -1.7% |
| 净利润同比 | -4.1% | 10.5% |
| 每股收益（稀释后） | $1.07 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMD
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $493.8M | ||
| Q3 25 | $1.7B | $492.9M | ||
| Q2 25 | $1.7B | $468.8M | ||
| Q1 25 | $1.7B | $458.4M | ||
| Q4 24 | $1.7B | $502.4M | ||
| Q3 24 | $1.6B | $511.2M | ||
| Q2 24 | $1.6B | $504.3M |
净利润AMD
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $33.7M | ||
| Q3 25 | $336.0M | $71.7M | ||
| Q2 25 | $215.0M | $39.3M | ||
| Q1 25 | $318.0M | $20.7M | ||
| Q4 24 | $351.0M | $30.5M | ||
| Q3 24 | $282.0M | $19.4M | ||
| Q2 24 | $308.0M | $-153.0M |
毛利率AMD
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AMD
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 9.9% | ||
| Q3 25 | 20.7% | 13.8% | ||
| Q2 25 | 18.0% | 12.8% | ||
| Q1 25 | 22.4% | 7.0% | ||
| Q4 24 | 24.0% | 7.8% | ||
| Q3 24 | 21.1% | 6.6% | ||
| Q2 24 | 23.1% | -31.3% |
净利率AMD
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 6.8% | ||
| Q3 25 | 19.3% | 14.5% | ||
| Q2 25 | 12.9% | 8.4% | ||
| Q1 25 | 18.9% | 4.5% | ||
| Q4 24 | 20.6% | 6.1% | ||
| Q3 24 | 17.9% | 3.8% | ||
| Q2 24 | 19.6% | -30.3% |
每股收益（稀释后）AMD
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.40 | ||
| Q3 25 | $1.18 | $0.84 | ||
| Q2 25 | $0.75 | $0.46 | ||
| Q1 25 | $1.11 | $0.24 | ||
| Q4 24 | $1.23 | $0.37 | ||
| Q3 24 | $0.97 | $0.23 | ||
| Q2 24 | $1.05 | $-1.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $375.2M |
| 总债务越低越好 | $3.0B | $570.5M |
| 股东权益账面价值 | $6.9B | $865.9M |
| 总资产 | $12.8B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资AMD
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $375.2M | ||
| Q3 25 | $1.5B | $340.1M | ||
| Q2 25 | $1.5B | $224.7M | ||
| Q1 25 | $1.5B | $99.0M | ||
| Q4 24 | $1.3B | $229.9M | ||
| Q3 24 | $1.8B | $103.8M | ||
| Q2 24 | $1.7B | $19.4M |
总债务AMD
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $570.5M | ||
| Q3 25 | $3.4B | $577.2M | ||
| Q2 25 | $3.3B | $583.9M | ||
| Q1 25 | $3.3B | $590.5M | ||
| Q4 24 | $3.3B | $597.1M | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AMD
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $865.9M | ||
| Q3 25 | $6.4B | $890.7M | ||
| Q2 25 | $6.1B | $833.8M | ||
| Q1 25 | $6.0B | $789.2M | ||
| Q4 24 | $5.9B | $764.9M | ||
| Q3 24 | $5.9B | $732.5M | ||
| Q2 24 | $6.2B | $706.5M |
总资产AMD
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $2.2B | ||
| Q3 25 | $12.2B | $2.2B | ||
| Q2 25 | $12.2B | $2.1B | ||
| Q1 25 | $11.9B | $2.0B | ||
| Q4 24 | $11.8B | $2.2B | ||
| Q3 24 | $11.0B | $2.1B | ||
| Q2 24 | $10.9B | $2.0B |
负债/权益比AMD
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.66× | ||
| Q3 25 | 0.53× | 0.65× | ||
| Q2 25 | 0.55× | 0.70× | ||
| Q1 25 | 0.56× | 0.75× | ||
| Q4 24 | 0.57× | 0.78× | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | 0.88× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流AMD
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $114.1M | ||
| Q3 25 | $362.0M | $137.3M | ||
| Q2 25 | $221.0M | $137.2M | ||
| Q1 25 | $431.0M | $-117.5M | ||
| Q4 24 | $481.0M | $133.0M | ||
| Q3 24 | $452.0M | $91.8M | ||
| Q2 24 | $333.0M | $107.0M |
自由现金流AMD
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $107.0M | — | ||
| Q1 25 | $334.0M | — | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | — |
自由现金流率AMD
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | — |
资本支出强度AMD
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 6.5% | — |
现金转化率AMD
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 3.39× | ||
| Q3 25 | 1.08× | 1.91× | ||
| Q2 25 | 1.03× | 3.49× | ||
| Q1 25 | 1.36× | -5.66× | ||
| Q4 24 | 1.37× | 4.36× | ||
| Q3 24 | 1.60× | 4.72× | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
